Cover Image
市場調查報告書

轉移性葡萄膜黑色素瘤的開發中產品分析

Metastatic Uveal Melanoma - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 305183
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
轉移性葡萄膜黑色素瘤的開發中產品分析 Metastatic Uveal Melanoma - Pipeline Review, H2 2014
出版日期: 2014年10月25日 內容資訊: 英文 58 Pages
簡介

所謂轉移性葡萄膜黑色素瘤是指由眼球(葡萄膜)發病,並轉移到人體其他部位的癌症。最常轉移到肝臟,其他肺、骨、皮下也很常見。主要的症狀為黃疸和皮膚的發癢·皮疹、肝臟內部酵素的異常增加、腹痛、食慾不振、噁心·嘔吐等。主要的治療方法有外科手術和化療、放射治療等。

本報告提供全球各國治療轉移性葡萄膜黑色素瘤用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

轉移性葡萄膜黑色素瘤概要

治療藥的開發

  • 轉移性葡萄膜黑色素瘤開發中產品:概要
  • 轉移性葡萄膜黑色素瘤開發中產品:比較分析

各企業開發中的轉移性葡萄膜黑色素瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

轉移性葡萄膜黑色素瘤治療藥:開發中的產品一覽(各企業)

轉移性葡萄膜黑色素瘤治療藥的開發企業

  • AstraZeneca PLC
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

轉移性葡萄膜黑色素瘤:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • selumetinib sulfate
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • sunitinib malate
  • vincristine sulfate liposomal
  • LY-2801653
  • sotrastaurin acetate
  • MEK-162

轉移性葡萄膜黑色素瘤治療藥:開發中產品的最新趨勢

轉移性葡萄膜黑色素瘤治療藥:暫停開發的產品

轉移性葡萄膜黑色素瘤的相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全2件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5642IDB

Summary

Global Markets Direct's, 'Metastatic Uveal Melanoma - Pipeline Review, H2 2014', provides an overview of the Metastatic Uveal Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Uveal Melanoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Uveal Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Uveal Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Uveal Melanoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Uveal Melanoma Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Uveal Melanoma - Overview
    • Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis
  • Metastatic Uveal Melanoma - Therapeutics under Development by Companies
  • Metastatic Uveal Melanoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Metastatic Uveal Melanoma - Products under Development by Companies
  • Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Novartis AG
    • Spectrum Pharmaceuticals, Inc.
  • Metastatic Uveal Melanoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-2801653 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • binimetinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metastatic Uveal Melanoma - Recent Pipeline Updates
  • Metastatic Uveal Melanoma - Dormant Projects
  • Metastatic Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2013: AstraZeneca's New Therapy Selumetinib Improves Progression-Free Survival And Shrink Tumors In Metastatic Uveal Melanoma, Researchers Report
      • May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2014
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by AstraZeneca PLC, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by GlaxoSmithKline plc, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2014
  • Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Metastatic Uveal Melanoma Therapeutics - Recent Pipeline Updates, H2 2014
  • Metastatic Uveal Melanoma - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2014
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top